rilimogene galvacirepvec/rilimogene glafolivec

AXP000178.1 · Cancer vaccine

Platform
poxvirus prime-boost (vaccinia prime, fowlpox boost)
Targets
KLK3
Originator
National Cancer Institute; Therion Biologics
Sponsor
Bavarian Nordic

Names

NameTypeSource
rilimogene galvacirepvec/rilimogene glafolivecpreferred namecurator
rilimogene galvacirepvecINNncit
rilimogene glafolivecINNncit
PROSTVACcodencit
PROSTVAC-VFcodencit
PROSTVAC-VF/TRICOMcodencit
PSA-TRICOMsynonymcurator
rF-PSA-TRICOMsynonymncit
rV-PSA-TRICOMsynonymncit

Virus

Role
Vaccine vector
Family
Poxviridae
Virus
vaccinia virus (NCBI Taxonomy 10245)
Strain
PROSTVAC-V (vaccinia) prime; PROSTVAC-F (fowlpox) boost
Replication
replicating
Modifications
PSA and TRICOM cassettes inserted; replication-competent vaccinia prime, non-replicating fowlpox boost
Transgenes
KLK3, CD80, ICAM1, CD58
Route
subcutaneous
Source
evidence

Cross-references

NCI Thesaurus
C132990

Approvals

No regulatory approval recorded.

Clinical trials (21)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT04020094Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate CancerWithdrawnPhase 22019-11-202021-04-090Prostate Adenocarcinoma
NCT03532217Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate CancerCompletedPhase 12018-09-142022-04-0119Metastatic Hormone-Sensitive Prostate Cancer
NCT03315871Combination Immunotherapy in Biochemically Recurrent Prostate CancerCompletedPhase 22018-03-202024-06-0440Prostate Cancer
NCT02933255PROSTVAC in Combination With Nivolumab in Men With Prostate CancerCompletedPhase 1/22017-04-182023-06-2024Prostate Cancer
NCT02506114Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate CancerTerminatedPhase 22016-10-062020-04-2215Prostatic Neoplasms
NCT02772562Adjuvant PROSTVAC-V/F in Subjects at High Risk for Relapse After Radical ProstatectomyTerminatedPhase 22016-07-182024-04-2933Prostatic Neoplasms
NCT02649855Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate CancerCompletedPhase 22016-01-192022-07-0174Neoplasms, Prostatic; Prostate Cancer; Prostate Neoplasms
NCT02649439Prostvac in Patients With Biochemically Recurrent Prostate CancerCompletedPhase 22015-12-222019-03-2897Prostate Cancer
NCT02326805PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active SurveillanceCompletedPhase 22015-06-032018-11-30154Stage I Prostate Adenocarcinoma AJCC v7; Stage II Prostate Adenocarcinoma AJCC v7
NCT02153918Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical ProstatectomyCompletedPhase 22014-05-312017-07-2827Neoplasms, Prostate; Prostate Cancer; Prostatic Neoplasms
NCT01867333Enzalutamide With or Without Vaccine Therapy for Advanced Prostate CancerCompletedPhase 22013-08-122022-09-2857Prostate Cancer
NCT01875250Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate CancerCompletedPhase 22013-07-222019-09-0138Prostate Cancer
NCT01322490A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate CancerCompletedPhase 32011-11-282017-09-251297Prostate Cancer Metastatic
NCT01145508Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate CancerTerminatedPhase 22010-082012-1010Hormone-Resistant Prostate Cancer; Prostate Adenocarcinoma; Recurrent Prostate Carcinoma; Stage IV Prostate Cancer
NCT00450463Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate CancerCompletedPhase 22007-02-232017-04-2764Prostate Cancer
NCT00108732A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate CancerCompletedPhase 22006-022010-1050Recurrent Prostate Carcinoma; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer
NCT00113984Vaccine and Antibody Treatment of Prostate CancerCompletedPhase 12005-06-082008-02-0130Prostatic Neoplasms
NCT00096551A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer With Local Failure Following Radiotherapy or Cryotherapy or Clinical Progression on Androgen Deprivation Therapy in the Absence of Local Definitive TherapyCompletedPhase 12004-11-012009-12-1121Prostatic Neoplasms
NCT00078585PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone TherapyCompletedPhase 22003-112006-01-04120Prostate Cancer
NCT00060528Sequential Vaccinations in Prostate Cancer PatientsCompletedPhase 1/22003-05-222006-03-0732Prostatic Neoplasms
NCT00001382A Phase I Study of Recombinant Vaccinia Virus That Expresses Prostate Specific Antigen in Adult Patients With Adenocarcinoma of the ProstateCompletedPhase 11994-0375Prostatic Neoplasms
Unconfirmed matches (1)

Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditionsMatched by
NCT00450619153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate CancerCompletedPhase 22007-022012-1144Prostate Cancername in title: PSA-TRICOM

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 42671172Long-Term Oncologic Outcomes of Neoadjuvant Tumor-Directed Immunotherapy (PROSTVAC) Before Radical Prostatectomy for Localized Prostate Cancer: A Secondary Analysis of a Neoadjuvant Trial.The Prostate2026name in title: PROSTVAC
PMID 40550568Programmed death-1 inhibition increases vaccine-induced T-cell infiltration in patients with prostate cancer.Journal for immunotherapy of cancer2025cited by trial NCT02933255
PMID 37858437Quantitative Analysis of Serial Positron Emission Tomography Imaging in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide.European urology oncology2024name in abstract: PROSTVAC
PMID 36517408A Phase 2, Double-blind, Randomized Controlled Trial of PROSTVAC in Prostate Cancer Patients on Active Surveillance.European urology focus2023name in title: PROSTVAC
PMID 37134294Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer.The oncologist2023cited by trial NCT00450463
PMID 33664086Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer.Journal for immunotherapy of cancer2021cited by trial NCT01875250
PMID 32269146Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer.Journal for immunotherapy of cancer2020cited by trial NCT02153918
PMID 30817251Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2019cited by trial NCT01322490
PMID 30197041A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study.European urology focus2018cited by trial NCT02326805
PMID 30563577Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report.Journal for immunotherapy of cancer2018name in title: PROSTVAC
PMID 27646950Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2017cited by trial NCT00078585
PMID 27486817Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial.Oncotarget2016name in abstract: PSA-TRICOM
PMID 25533418A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802.European urology2015name in abstract: PROSTVAC
PMID 26111351Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809).Human vaccines & immunotherapeutics2015name in title: PSA-TRICOM
PMID 24474335Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets.International journal of cancer2014name in abstract: rV-PSA-TRICOM
PMID 24514956A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates.Cancer immunology, immunotherapy : CII2014name in abstract: PROSTVAC
PMID 24733910Humoral response to a viral glycan correlates with survival on PROSTVAC-VF.Proceedings of the National Academy of Sciences of the United States of America2014name in title: PROSTVAC-VF
PMID 24778277Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer.Cancer immunology research2014name in title: PSA-TRICOM
PMID 23836412Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer.Cancer immunology, immunotherapy : CII2013name in abstract: rV-PSA-TRICOM
PMID 22326924Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.The Lancet. Oncology2012name in abstract: PSA-TRICOM
PMID 20976449Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination.Cancer immunology, immunotherapy : CII2011name in abstract: PSA-TRICOM
PMID 20100959Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2010cited by trial NCT00078585
PMID 17707059cited by trial NCT00060528
PMID 22932804cited by trial NCT00060528

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 38277189Nonsurgical Interventions to Prevent Disease Progression in Prostate Cancer Patients on Active Surveillance: A Systematic Review and Meta-analysis.European urology oncology2024name in abstract: PROSTVAC
PMID 36835981Immunotherapy for Prostate Cancer: A Current Systematic Review and Patient Centric Perspectives.Journal of clinical medicine2023name in abstract: PROSTVAC
PMID 33866131Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancer.Nuclear medicine and biology2021name in abstract: PROSTVAC
PMID 34729217Therapeutic metastatic prostate cancer vaccines: lessons learnt from urologic oncology.Central European journal of urology2021name in abstract: PROSTVAC
PMID 31350066Re: Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-resistant Prostate Cancer.European urology2020name in title: PROSTVAC
PMID 32057540Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure.Annals of oncology : official journal of the European Society for Medical Oncology2020name in abstract: PROSTVAC
PMID 30913454Emerging therapeutic targets for patients with advanced prostate cancer.Cancer treatment reviews2019name in abstract: PROSTVAC-VF
PMID 31482315Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: Past and Future Strategies for Optimization.Current urology reports2019name in abstract: PROSTVAC
PMID 29231062Promising immunotherapy for prostate cancer.Expert opinion on biological therapy2018name in abstract: PSA-TRICOM
PMID 29709495Morphological changes induced by intraprostatic PSA-based vaccine in prostate cancer biopsies (phase I clinical trial).Human pathology2018name in abstract: PSA-TRICOM
PMID 28376158Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment.Journal of the National Cancer Institute2017name in abstract: PSA-TRICOM
PMID 28771597Development and validation of a Luminex assay for detection of a predictive biomarker for PROSTVAC-VF therapy.PloS one2017name in title: PROSTVAC-VF
PMID 29146441Combining immunotherapies for the treatment of prostate cancer.Urologic oncology2017name in abstract: PSA-TRICOM
PMID 29183736Immunotherapy in the Elderly.European urology focus2017name in abstract: PROSTVAC
PMID 26977847The evolving role of immunotherapy in prostate cancer.Current opinion in oncology2016name in abstract: PROSTVAC
PMID 27076165Cancer Vaccines: A Brief Overview.Methods in molecular biology (Clifton, N.J.)2016name in abstract: PROSTVAC-VF
PMID 27485137Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy.Cancer immunology research2016name in abstract: PROSTVAC
PMID 27749327Immune Therapy for Prostate Cancer.Cancer journal (Sudbury, Mass.)2016name in abstract: PSA-TRICOM
PMID 25747158Cancer vaccines: can they improve survival?Cancer biotherapy & radiopharmaceuticals2015name in abstract: PROSTVAC-VF
PMID 25894495Immunotherapy in prostate cancer.Current urology reports2015name in abstract: PSA-TRICOM
PMID 26022286[New therapies in metastatic castration resistant prostate cancer].Bulletin du cancer2015name in abstract: PROSTVAC-VF
PMID 26060311Correction for Campbell et al., Humoral response to a viral glycan correlates with survival on PROSTVAC-VF.Proceedings of the National Academy of Sciences of the United States of America2015name in title: PROSTVAC-VF
PMID 26161414Beyond the Immune Suppression: The Immunotherapy in Prostate Cancer.BioMed research international2015name in abstract: PROSTVAC-VF
PMID 26235179Development of PROSTVAC immunotherapy in prostate cancer.Future oncology (London, England)2015name in title: PROSTVAC
PMID 26338967ABO blood type correlates with survival on prostate cancer vaccine therapy.Oncotarget2015name in abstract: PROSTVAC-VF
PMID 24402184Beyond sipuleucel-T: immune approaches to treating prostate cancer.Current treatment options in oncology2014name in abstract: PROSTVAC-VF
PMID 24435055Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications.Asian journal of andrology2014name in abstract: PSA-TRICOM
PMID 24477411Immunotherapy for prostate cancer: recent developments and future challenges.Cancer metastasis reviews2014name in abstract: PROSTVAC-VF
PMID 24571737Targeting kallikrein-related peptidases in prostate cancer.Expert opinion on therapeutic targets2014name in abstract: PROSTVAC
PMID 24620782Sipuleucel-T and immunotherapy in the treatment of prostate cancer.Expert opinion on biological therapy2014name in abstract: PROSTVAC
PMID 24762070PROSTVAC® targeted immunotherapy candidate for prostate cancer.Immunotherapy2014name in title: PROSTVAC
PMID 24775724Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.The Canadian journal of urology2014name in abstract: PSA-TRICOM
PMID 24858824The use of the EVITA algorithm for clinical assessment of novel agents used in prostate cancer, metastatic melanoma, and systemic lupus erythematosus.European journal of clinical pharmacology2014name in abstract: PROSTVAC
PMID 25097802Poxviral-based vaccine elicits immunologic responses in prostate cancer patients.Oncoimmunology2014name in abstract: PROSTVAC
PMID 25177493Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances.Therapeutic advances in vaccines2014name in abstract: PSA-TRICOM
PMID 25259804Molecular insights into the development of T cell-based immunotherapy for prostate cancer.Expert review of clinical immunology2014name in abstract: PROSTVAC-VF
PMID 25328681Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy.Journal for immunotherapy of cancer2014name in title: PROSTVAC
PMID 25518354[Current status and prospects of immunotherapy for castration-resistant prostate cancer].Nihon rinsho. Japanese journal of clinical medicine2014name in abstract: PROSTVAC-VF
PMID 23272970Castration resistant prostate cancer (CRPC): state of the art, perspectives and new challenges.Anti-cancer agents in medicinal chemistry2013name in abstract: PROSTVAC-VF
PMID 23337757Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies.Cancer journal (Sudbury, Mass.)2013name in abstract: PSA-TRICOM
PMID 23362327Serum antibodies to blood group A predict survival on PROSTVAC-VF.Clinical cancer research : an official journal of the American Association for Cancer Research2013name in title: PROSTVAC-VF
PMID 23714490Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer: current progress and clinical applications.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting2013name in abstract: PSA-TRICOM
PMID 23757912[Immunotherapy: a therapeutic revolution against prostate cancer?].Revue medicale suisse2013name in abstract: PROSTVAC-VF
PMID 23880851Recent progress in pharmaceutical therapies for castration-resistant prostate cancer.International journal of molecular sciences2013name in abstract: PROSTVAC
PMID 24166056[New therapy concepts for castration-resistant prostate cancer: between hormone manipulation, targeted therapy and chemotherapy].Der Urologe. Ausg. A2013name in abstract: PROSTVAC
PMID 21748753Emerging treatment options for patients with castration-resistant prostate cancer.The Prostate2012name in abstract: PROSTVAC
PMID 22001436Current vaccination strategies for prostate cancer.European urology2012name in abstract: PROSTVAC-VF
PMID 22209376Novel molecular targets for the therapy of castration-resistant prostate cancer.European urology2012name in abstract: PROSTVAC-VF/TRICOM
PMID 22295041Emerging novel therapies for advanced prostate cancer.Therapeutic advances in urology2012name in abstract: PROSTVAC-VF
PMID 22328018Current status of immunological approaches for the treatment of prostate cancer.Current opinion in urology2012name in abstract: PROSTVAC-VF
PMID 22393799Optimizing outcomes of advanced prostate cancer: drug sequencing and novel therapeutic approaches.Oncology (Williston Park, N.Y.)2012name in abstract: PROSTVAC-VF
PMID 22413824Poxviral vectors for cancer immunotherapy.Expert opinion on biological therapy2012name in abstract: PROSTVAC-VF
PMID 22595052Clinical evaluation of TRICOM vector therapeutic cancer vaccines.Seminars in oncology2012name in abstract: rF-PSA-TRICOM
PMID 22666217Emerging targeted therapies for castration-resistant prostate cancer.Frontiers in endocrinology2012name in abstract: PROSTVAC-VF
PMID 22672122New developments in castrate-resistant prostate cancer.BJU international2012name in abstract: PROSTVAC
PMID 22913261Prostate cancer vaccines in clinical trials.Expert review of vaccines2012name in abstract: PROSTVAC
PMID 22918924The evolving role of immunotherapy in prostate cancer.Annals of oncology : official journal of the European Society for Medical Oncology2012name in abstract: PROSTVAC-VF
PMID 23040162Integration of immunotherapy into the management of advanced prostate cancer.Urologic oncology2012name in abstract: PROSTVAC
PMID 23138168New agents in metastatic prostate cancer.Journal of the National Comprehensive Cancer Network : JNCCN2012name in abstract: PROSTVAC-VF
PMID 23213665News studies: combining PROSTVAC with conventional cancer therapy.Human vaccines & immunotherapeutics2012name in title: PROSTVAC
PMID 23236591[The treatment of castration-resistant prostate cancer].Magyar onkologia2012name in abstract: PROSTVAC-VF
PMID 21106727Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy.Clinical cancer research : an official journal of the American Association for Cancer Research2011name in abstract: PSA-TRICOM
PMID 21311328Novel agents and new therapeutics in castration-resistant prostate cancer.Current opinion in oncology2011name in abstract: PROSTVAC
PMID 21675925Recent advances in immunotherapy for the treatment of prostate cancer.Expert opinion on biological therapy2011name in abstract: PROSTVAC-VF/TRICOM
PMID 21700764Prostate cancer immunotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research2011name in abstract: PROSTVAC-VF
PMID 21741424Immunotherapy in prostate cancer: emerging strategies against a formidable foe.Vaccine2011name in abstract: PSA-TRICOM
PMID 21825260Immunotherapy for prostate cancer: biology and therapeutic approaches.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2011name in abstract: PROSTVAC-VF
PMID 20140811A year of successful cancer vaccines points to a path forward.Current opinion in molecular therapeutics2010name in abstract: PROSTVAC-VF/TRICOM
PMID 20140819Therapeutic vaccines for prostate cancer.Current opinion in molecular therapeutics2010name in abstract: PROSTVAC-VF/TRICOM
PMID 20179598Current status of immunological therapies for prostate cancer.Current opinion in urology2010name in abstract: PROSTVAC
PMID 20209643Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice.The Prostate2010name in abstract: PROSTVAC
PMID 21208850The current and emerging role of immunotherapy in prostate cancer.Clinical genitourinary cancer2010name in abstract: PROSTVAC
PMID 19548854Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.Expert opinion on investigational drugs2009name in title: PROSTVAC-VF
PMID 18985183Gateways to clinical trials.Methods and findings in experimental and clinical pharmacology2008name in abstract: rV-PSA-TRICOM
PMID 17458173Drug evaluation: Therion's rV-PSA-TRICOM + rF-PSA-TRICOM prime-boost prostate cancer vaccine.Current opinion in molecular therapeutics2007name in title: rV-PSA-TRICOM
PMID 16390546A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer.Journal of translational medicine2006name in title: PROSTVAC-VF
PMID 17084174Management of high risk metastatic prostate cancer: the case for novel therapies.The Journal of urology2006name in abstract: PROSTVAC-VF
PMID 15945343Recent progress in management of advanced prostate cancer.Oncology (Williston Park, N.Y.)2005name in abstract: PROSTVAC
PMID 16179960Gateways to clinical trials.Methods and findings in experimental and clinical pharmacology2005name in abstract: PROSTVAC-VF
PMID 12435056Technology evaluation: PROSTVAC, Therion.Current opinion in molecular therapeutics2002name in title: PROSTVAC
PMID 9933036Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer.Urology1999name in title: PROSTVAC

NIH grants

ProjectTitleOrganisationPIYearsLinked by
ZIABC010598Human Immune Responses to Tumor Antigens for Cancer ImmunotherapyDIVISION OF BASIC SCIENCES - NCISCHLOM, JEFFREY2012–2025name in abstract: PSA-TRICOM
ZIABC010666Cancer ImmunotherapyDIVISION OF BASIC SCIENCES - NCIGULLEY, JAMES L.2009–2025name in abstract: PROSTVAC-VF
ZICBC010981Biomarker Investigations for Clinical TrialsDIVISION OF BASIC SCIENCES - NCIHESELMEYER, KERSTIN2025–2025name in abstract: PROSTVAC
ZICBC012029Tumor Immune MicroEnvironment Facility (Scientific Core)DIVISION OF BASIC SCIENCES - NCILASSOUED, WIEM2021–2025name in abstract: PROSTVAC
ZIABC010944Strategies for Cancer Immunotherapy Development: Preclinical StudiesDIVISION OF BASIC SCIENCES - NCISCHLOM, JEFFREY2011–2024name in abstract: PSA-TRICOM
ZIABC010425Strategies for Cancer Immunotherapy Clinical TrialsDIVISION OF BASIC SCIENCES - NCISCHLOM, JEFFREY2009–2023name in abstract: rV-PSA-TRICOM
ZIABC011055Serum Antibody Profiling with a Carbohydrate MicroarrayDIVISION OF BASIC SCIENCES - NCIGILDERSLEEVE, JEFFREY2009–2023name in abstract: PROSTVAC-VF
ZIABC011896Evaluation of novel treatments in biochemically recurrent prostateDIVISION OF BASIC SCIENCES - NCIMADAN, RAVI2019–2023name in abstract: PSA-TRICOM
ZIABC010945Clinical trials employing cancer vaccine combination therapiesDIVISION OF BASIC SCIENCES - NCIGULLEY, JAMES L.2009–2022name in abstract: PSA-TRICOM
ZIABC011547Cancer Immunotherapy Clinical TrialsDIVISION OF BASIC SCIENCES - NCISTRAUSS, JULIUS2014–2022name in abstract: rF-PSA-TRICOM
ZIABC011897Evaluation of Immune-based Combinations in Metastatic Prostate CancerDIVISION OF BASIC SCIENCES - NCIMADAN, RAVI2019–2021name in abstract: PROSTVAC
ZIABC012060Novel Anti-androgen strategies in Prostate CancerDIVISION OF BASIC SCIENCES - NCIMADAN, RAVI2021–2021name in abstract: PROSTVAC
26120120003PHASE II, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF PROSTVAC (PSA-TRICOM) IN PATIENTS... (PROTOCOL UAZ2012-03-01). CONTRACTOR: UNIVERSITY OF ARIZONA. CONTRACT: HHSN261201200031I. PERIOD: 9UNIVERSITY OF ARIZONACHOW, SHERY2014–2020name in title: PSA-TRICOM
ZIASC010098The Evaluation of Novel Therapeutics for Genitourinary MalignanciesDIVISION OF CLINICAL SCIENCES - NCIDAHUT, WILLIAM L.2009–2020name in abstract: rF-PSA-TRICOM
U01CA202939Developing clinical, immunologic and radiographic tools to measure the clinical effect of immunotherapy in biochemically recurrent prostate cancerSLOAN-KETTERING INST CAN RESEARCHKANTOFF, PHILIP W2016–2018name in abstract: PROSTVAC
U54MD010706Sociobiological Responses to Stress in Prostate Cancer SurvivorsMEDICAL UNIVERSITY OF SOUTH CAROLINAHUGHES-HALBERT, CHANITA A.2016–2016name in abstract: PROSTVAC
ZIABC010972Identification of human tumor-associated antigensDIVISION OF BASIC SCIENCES - NCITSANG, KWONG YOK2009–2016name in abstract: rV-PSA-TRICOM
ZIABC010973Analyses of human T regulatory cellsDIVISION OF BASIC SCIENCES - NCITSANG, KWONG YOK2009–2016name in abstract: rV-PSA-TRICOM
ZIABC011281Combination therapies involving novel cancer vaccinesDIVISION OF BASIC SCIENCES - NCIMADAN, RAVI2010–2013name in abstract: PROSTVAC-VF
ZIABC011280Cancer Therapy Trials using novel vaccine platformsDIVISION OF BASIC SCIENCES - NCIMADAN, RAVI2010–2012name in abstract: PROSTVAC-VF
Z01BC010666Cancer Therapy Clinical Trials Using Novel Recombinant VaccinesDIVISION OF BASIC SCIENCES - NCIGULLEY, JAMES L.2006–2008name in abstract: rF-PSA-TRICOM
Z01SC010098The Evaluation of Novel Therapeutics for Genitourinary MalignanciesDIVISION OF CLINICAL SCIENCES - NCIDAHUT, WILLIAM L.2008–2008name in abstract: PSA-TRICOM
Z01BC010662Vaccine Clinical TrialsDIVISION OF BASIC SCIENCES - NCIARLEN, PHILIP M2006–2007name in abstract: rV-PSA-TRICOM
M01RR000056PH II RNDM DBL BLIND CONTRL'D STDY EVAL SFTY AND EFFICACY PROSTVAC-VF/TRICOMUNIVERSITY OF PITTSBURGH AT PITTSBURGHCHATTA, GURKAMAL S2005–2005name in title: PROSTVAC-VF/TRICOM
M01RR000042RECOMBINANT VACCINIA/PSA VACCINE IN PATIENTS WITH RECURRENCE OF PROSTATE CANCERUNIVERSITY OF MICHIGAN AT ANN ARBORSANDA, MARTIN G1999–1999name in abstract: PROSTVAC

Notes

PROSTVAC: vaccinia-PSA-TRICOM prime (rilimogene galvacirepvec, NCIt C38681, UNII 59WJ3TGA5K) followed by fowlpox-PSA-TRICOM boosts (rilimogene glafolivec, NCIt C29560, UNII 7PLH7RM47T); recorded as one program because it is one prime-boost product with a single combined INN pair and NCIt concept (C132990). unii left empty because the product has two. Phase 3 PROSPECT (1,297 men, mCRPC) stopped for futility at interim analysis, reported September 2017. PSA is KLK3; TRICOM = CD80 (B7.1), ICAM1, CD58 (LFA-3).

How to cite

rilimogene galvacirepvec/rilimogene glafolivec (AXP000178.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000178.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.